CN102793696B - Application of butylphthalide in preparation of medicament for treating bronchial asthma - Google Patents
Application of butylphthalide in preparation of medicament for treating bronchial asthma Download PDFInfo
- Publication number
- CN102793696B CN102793696B CN201210316146.8A CN201210316146A CN102793696B CN 102793696 B CN102793696 B CN 102793696B CN 201210316146 A CN201210316146 A CN 201210316146A CN 102793696 B CN102793696 B CN 102793696B
- Authority
- CN
- China
- Prior art keywords
- butyphthalide
- butylphthalide
- asthma
- guinea pig
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides novel medical application of butylphthalide, i.e. the application of the butylphthalide in the preparation of a medicament for treating the bronchial asthma. The experimental research on the spasmolysis of the butylphthalide on the isolated tracheal smooth muscle of a guinea pig and the influence of the butylphthalide on the incubation period of asthma of the guinea pig shows that the butylphthalide in the concentration range of 3.68*10-6 to 3.68*10-4g/mL has obvious spasmolysis on the tracheal smooth muscle of the guinea pig in the isolated spasticity caused by 5*10-6g/mL of acetylcholine or histamine. On the basis of continuously applying the butylphthalide to the guinea pig which is sensitive for the acetylcholine and the histamine for 10 days, a mixture of the acetylcholine and the histamine is atomized and sucked and the incubation period of asthma is observed. A result shows that 30 mg/kg and 90 mg/kg of butylphthalide has an effect of relieving the tracheospasm of the guinea pig, which is caused by the acetylcholine and the histamine. Therefore, the butylphthalide has a treatment effect on the asthma guinea pig and the treatment effect of the butylphthalide on the asthma guinea pig is related to the effect of inhibiting Ca2+ inner flow and expanded tracheal smooth muscle of the butylphthalide.
Description
Technical field
The invention belongs to field of medicaments, relate to a kind of medical usage of compound butyphthalide, relate in particular to the application in preparation prevention or treatment bronchial asthma as active component of a kind of compound butyphthalide.
Background technology
Bronchial asthma (abbreviation asthma) is by the multiple inflammatory cell chronic airway inflammation disease that particularly mastocyte, eosinophilic granulocyte and T lymphocyte participate in, in susceptible person, this kind of inflammation can cause the symptoms such as the panting of outbreak repeatedly, tachypnea, uncomfortable in chest and cough, how at night or morning, showing effect, air flue increases multiple stimulating factor reactivity.It is 1%-18% that 2006 editions GINA (The Global Initiative for Asthma, GINA) propose global asthma prevalence, and approximately there are 300,000,000 asthmatic patients in the whole world; Prevalence in China's asthma is about 2%, and child Ke Da 4% approximately has 20,000,000 above asthmatic patients according to the measuring and calculating whole nation, and asthma has become a kind of main chronic disease of serious threat public health.
At present, the chemical drugs for the treatment of asthma mainly contains glucocorticoid, β
2the medicines such as receptor agonism medicine and xanthine, though determined curative effect is reliable, untoward reaction is larger.Glucocorticoid is evident in efficacy, but effect extensively, and life-time service easily causes multiple serious adverse reaction; β
2receptor agonism medicine is the common medicine of asthma in acute attack, and xanthine drug is applicable to various asthma, but they can excited heart in performance therapeutical effect, even causes arrhythmia.Simultaneously, although recent two decades has taked to comprise the comprehensive anti-inflammatory treatment scheme of inhaled, but Epidemiological study is found sickness rate, the mortality rate of asthma and is not reduced (Su Kuiguo thereupon, Jiang Liangduo, Guo Yongying, etc. the impact [J] of Sang Su drink on Brown-Norway rats with asthma Airway Remodeling and lung tissue epithelial cell ICAM-1 expression. Shandong Traditional Chinese Medicine University's journal, 2010,34 (4): 354-357.), still in the urgent need to going to find new method, prevent and treat asthma.
Butyphthalide (Butylphthalide, NBP), can be levo form, d-isomer and raceme, and chemical formula is C
12h
14o
2, relative molecular weight is 190.24, chemical structural formula is as follows:
At present, because butyphthalide has protective wire plastochondria, improves brain energy metabolism and suppresses Ca
2+the effects such as interior stream, are used for the treatment of light, moderate acute ischemic cerebral apoplexy clinically.Known according to the pharma-toxicology Experiment and clinic presentations result of the test of butyphthalide treatment cerebral infarction, butyphthalide pharmacologically active is high, untoward reaction is little.
Summary of the invention
The medical usage that the object of this invention is to provide a kind of butyphthalide---the application in preparation treatment bronchial asthma medicine.
The application of butyphthalide of the present invention in preparation prevention or treatment bronchial asthma medicine, to take butyphthalide as main active, according to technique available on pharmaceutics and adjuvant, be prepared into any preparation, as soft capsule, drop pill, tablet, lyophilized injectable powder or injection etc.
Described butyphthalide combines with the medicine (as aminophylline, Oxtriphylline, diprophylline, ephedrine, albuterol, Clenbuterol, sodium cromoglicate, ipratropium bromide, beclometasone, budesonide, nifedipine etc.) with treatment asthma function, jointly as active substance, make the effect of each medicine produce synergism, further to strengthen its drug effect.
Butyphthalide of the present invention can exist with the form of levo form, d-isomer or raceme.
Below by zoopery, the activity of butyphthalide is elaborated.
One, the spasmolysis of butyphthalide to guinea-pig isolated tracheal smooth muscle
In the isolated tracheal smooth muscle experiment of relievining asthma, common are trachea sheet, annulus trachealis, trachea flight and tracheal volume method etc., wherein simple to operate with trachea sheet method, systematic error is less (to be difficult to trachea to be cut into the flight that width is equal in trachea flight method, the around-France systematic error of tracheal volume method and trachea is larger), therefore adopt trachea sheet experimental technique to study the spasmolysis of butyphthalide to guinea-pig isolated tracheal smooth muscle in this experiment.
1 experiment material
1.1 reagent and instrument: butylbenzene peptide, Products in China inspection institute, lot number: 101035-200901; Aminophylline, Zhu Yi Jin pharmaceutcal corporation, Ltd of upper Hisense, the accurate word H20033430 of traditional Chinese medicines.Get respectively said medicine or composition, put in mortar, add appropriate tween 80, adopt dry gum method in “ You ﹕ Jiao ﹕ water=2 ﹕ 1 ﹕ 2 " ratio prepare colostrum, suitable dilution obtains the Emulsion of butyphthalide and aminophylline; Separately get appropriate tween 80 and prepare 2% solution liquid in contrast, put 2 ~ 4 ℃ of refrigerator cold-storages standby.Acetylcholine (Ach), Aladdin reagent company, lot number: 40837; Histamine phosphate (Hist), Aladdin reagent company, lot number: 47835; Tween 80, Shanghai Dazhong Pharmaceutical Manufacturer, lot number: 700934; All the other reagent are analytical pure.HB-2 Xing Er road physiograph, Chengdu Instruement Factory; HU-1 type muscular tension transducer, Huaibei Zhenghua Biological Instrument Co., Ltd.; HH-S type electric-heated thermostatic water bath, Medical Apparatus & Instruments Factory Jiangsu Prov.; BS1103 type Sartorius electronic analytical balance, Beijing Sai Duolisi Instrument Ltd..
1.2 laboratory animals: Cavia porcellus, body weight 250～350g, male and female dual-purpose, is provided by Lanzhou Veterinary Inst., Chinese Acedemy of Agaricultural Sciences, animal production licence number: SCXK-2005.
2. experimental technique
2.1. the preparation of isolated helical strips of guinea: reference gas section of jurisdiction method, get Cavia porcellus and hit its hindbrain to dusk with rod, plane leaves neck to skin of chest muscle immediately, take off the complete trachea section from larynx to trachea crotch, put into and fill oxygen-saturated Krebs-Henseleit (K-H) nutritional solution (every liter containing solute NaCl 6.92g, KCl 0.35g, CaCl
20.28g, KH
2pO
40.16g, MgSO
4(7H
2o) 0.29g, NaHCO
32.1g, Glu 2.0) culture dish in, peel off gently the outer attached tissue of trachea, with K-H nutritional solution, rinse clean tube chamber content.Trachea is longitudinally cut off from cartilage center line (breast side), moved towards equalization be afterwards cut into 6 sections along cartilage, by alternate 3 sections of tracheas along vertical plane suturing with thread management together, one end is fixed on the little hook of L-type breather, and the other end hangs on transducer with surgical thread.Whole device is put into 10mL constant temperature (37 ± 0.5 ℃) maxwell bath pipe, per minute logical containing 95%O
2and 5%CO
2the about 15-20 of a gaseous mixture bubble; The parameter of two road physiographs, in Table 1, records muscular tension and changes, and adjusting trachea rest tension is 1g, and every 40min changes nutritional solution 1 time, and balance approximately starts test after 30 ~ 60min.
The parameter setting of table 1 two road physiographs
2.2. butyphthalide causes to Ach the spasmolysis that guinea-pig isolated tracheal smooth muscle shrinks: after specimen is stable, retouch one section of normalized curve of meter, start afterwards dosing, retouch meter tracheal smooth muscle easypro contracting curve in 10min under drug effect.Be specially: retouch that in meter normalized curve backward maxwell bath pipe, to add 0.05% Ach 0.1mL(final concentration be 5 * 10
-6g/mL), record the curve that tracheal smooth muscle spasm shrinks, after tracheal smooth muscle contractile response reaches maximum and stablizes, by accumulative total method for dosing medicine, add successively 0.0368%, 0.3312%, 3.312% butyphthalide 0.1mL, butyphthalide final concentration in nutritional solution reaches respectively 0.000368%, 0.00368%, 0.0368%, the spasmolysis of observation medicine to spasm tracheal smooth muscle, every minor tick 10min gives next high concentration when the reaction of last concentration reaches flat-top again.With 37 ℃ of nutritional solutions, rinse trachea 3 ~ 5 times, after ready to balance, by order shown in table 2, repeat aforesaid operations, trace Ach and make curve that tracheal smooth muscle spasm shrinks and the spasmolysis of aminophylline, take and contrast liquid and test as blank, be calculated as follows spasmolytic rate (%).
Table 2 Latin square design order of addition of ingredients table
Note: A represents butyphthalide, B represents aminophylline, C represents 2% tween 80
2.3. butyphthalide causes to Hist the spasmolysis that guinea-pig isolated tracheal smooth muscle shrinks: method is with under 2.2, after specimen is stable, to adding 0.05% Hist 0.1mL(final concentration in maxwell bath pipe, is first 5 * 10
-6g/mL), after tracheal smooth muscle spasm contraction reaches maximum and stablizes, by table 2 order accumulative total, add butyphthalide, aminophylline or contrast liquid, record is subject to the spasmolysis of reagent and calculates spasmolytic rate.
2.4. date processing experimental data employing (
±
s) form represent, between group, relatively adopt one factor analysis of variance (One-way ANOVA), application SPSS11.5 statistical software carry out descriptive statistics and analysis, with
p< 0.05 He
p< 0.01 indicates statistical significance.
3. experimental result
3.1. butyphthalide causes to Ach the spasmolysis that guinea-pig isolated tracheal smooth muscle shrinks: in Table 3.As can be seen from Table 3,3.68 * 10
-6~ 3.68 * 10
-4the guinea pig tracheal smooth muscle of the in vitro spasticity that the butyphthalide in mL/mL concentration range causes Ach have significant spasmolysis and its spasmolysis have obvious dose-effect relationship (
p< 0.01).
Table 3 butyphthalide to Ach cause the spasmolysis that guinea-pig isolated tracheal smooth muscle shrinks (
±
s, n=10)
Note: with the comparison of blank group:
2) p< 0.01; With middle concentration ratio:
4) p< 0.01.
3.2. butyphthalide causes that to Hist the spasmolysis experimental result that guinea-pig isolated tracheal smooth muscle shrinks shows, 3.68 * 10
-6~ 3.68 * 10
-4the guinea pig tracheal smooth muscle of the in vitro spasticity that the butyphthalide in mL/mL concentration range causes Hist have significant spasmolysis (
p< 0.01), simultaneously its spasmolysis have certain dose-effect relationship (
p< 0.05,0.01).The results are shown in Table 4.
Table 4 butyphthalide to Hist cause the spasmolysis that guinea-pig isolated tracheal smooth muscle shrinks (
±
s, n=10)
Note: with the comparison of blank group:
2) p< 0.01; With middle concentration ratio:
3) p< 0.05
4) p< 0.01.
First this experiment causes the spastic contraction of guinea pig tracheal smooth muscle with causing convulsion agent, observes on this basis the spasmolysis of butyphthalide; Result of study demonstration, butyphthalide has significant spasmolysis and its effect to have certain dose-effect relationship to the guinea pig tracheal smooth muscle of in vitro spasticity.
Two, butyphthalide draws and breathes heavily impact incubation period Cavia porcellus
Constant-pressure atomization Hist and Ach cause that Cavia porcellus twitches, the incubation period of record " asthma reaction ", the antiasthmatic effect of investigation medicine.
1. experiment material
1.1. medicine and reagent: Phthalide soft capsule (trade name En Bipu soft capsule is called for short NBP): authentication code: the accurate word H20050299 of traditional Chinese medicines, Enbipu Pharmacy Co., Ltd., Shiyao Group. produces, batch number: 11040611; Dexamethasone acetate tablets, Pharmaceutical Xinzheng, Tianjin pharmaceutical Co. Ltd produces, authentication code: the accurate word H41021038 of traditional Chinese medicines.Histamine (Hist), Sigma chemical reagents corporation, batch number: 951007; Acetylcholine (Ach), Sigma chemical reagents corporation, batch number: 951209; Poloxamer-188, German BASF AG produces.During experiment, with butyphthalide emulsion and the 0.0225% dexamethasone emulsion of 0.5% poloxamer-188 preparation 0.3%, 0.9%, separately prepare the contrast liquid of 0.5% poloxamer-188, cold preservation is standby.
1.2. laboratory animal: Cavia porcellus, ♂ ♀ dual-purpose, 150 ± 30 grams of body weight, are provided by Lanzhou Veterinary Inst., Chinese Acedemy of Agaricultural Sciences, animal production licence number: SCXK-2005.
2. experimental technique
2.1 screening groupings: reference in its entirety animal pharmaceuticals draw the method for breathing heavily (Xu Shuyun. pharmacological experimental methodology [M]. Beijing: People's Health Publisher, 1982:921-913.), get the healthy guinea pig of body weight 150g ± 30g, ♂ ♀ dual-purpose.First put into glass bell jar (the about 4L of volume) and be familiar with environment, after its peace and quiet, with the pressure of 400mmHg, spray into 15 seconds of mixed liquor (1:1) of 2%Ach and 0.1%Hist.There is asthma attack in observation Cavia porcellus, breathe be the devil, time of the rolling of even twitching, draw and breathe heavily incubation period, surpass 120 seconds still nonresponder be insensitive Cavia porcellus, give it up.The Cavia porcellus that preliminary election is qualified is divided into 4 groups by sex body weight stratified random: Normal group, positive controls, butyphthalide heavy dose are organized and butyphthalide small dose group.
2.2. animals administer: above-mentioned each treated animal is pressed 10mL/kg administration every day: Normal group ig contrasts liquid, positive controls ig dexamethasone 2.25mg/kg, the heavy dose of group of butyphthalide and small dose group be ig butyphthalide 90mg/kg and 30mg/kg respectively.Every day 1 time, continuous 10 days.
2.3. measure to draw and breathe heavily incubation period: after the 10th day administration 1h, by the method for screening animal, redeterminate and draw the number of animals of breathing heavily asthma attack in incubation period and 80 seconds and causing animal to fall.If during the symptom of still rolling without tic over 6min, calculated by 6min.
2.4. data statistics and analysis: application SPSS12.0 statistical software, to draw breathe heavily adopt incubation period t check organize between relatively, to falling in 80 seconds, number of animals adopts χ
2check is compared between organizing; With
p< 0.05 He
p< 0.01 indicates statistical significance.
3. experimental result
From table 5, the asthma attack incubation period of butyphthalide energy significant prolongation Cavia porcellus and its curative effect in test dose scope (30 ~ 90mg/kg), be obvious dose-effect relationship (
p< 0.01).Experiment shows that butyphthalide has the Ach of alleviation and Hist brings out the effect of guinea pig trachea spasm.
Table 5 butyphthalide on Cavia porcellus draw breathe heavily preclinical impact (
±
s,
n=8)
Note: with the comparison of blank group:
1) p< 0.05
2) p< 0.01; With butyphthalide small dose group:
4) p< 0.01.
This experiment is being given on the butyphthalide basis of 10 days, adopts constant-pressure atomization cause convulsion agent simulation Experimental Asthma In Guinea-pigs and then twitch, by the antiasthmatic effect of observing butyphthalide incubation period of record " asthma reaction "; Result of study shows, asthma incubation period of butyphthalide energy significant prolongation Cavia porcellus and have certain dose-effect relationship.
Above-mentionedly by butyphthalide, the spasmolysis of guinea-pig isolated tracheal smooth muscle and butyphthalide are drawn to the experimentation of breathing heavily preclinical impact to Cavia porcellus and show, 3.68 * 10
-6~ 3.68 * 10
-4butyphthalide in g/mL concentration range is to 5 * 10
-6the guinea pig tracheal smooth muscle of the in vitro spasticity that g/mL acetylcholine or histamine cause has significant spasmolysis.The Cavia porcellus of acetylcholine and histamine sensitivity is given on the butyphthalide basis of 10 days continuously, and atomization sucks the mixture of acetylcholine and histamine, observes drawing and breathes heavily incubation period.Result demonstration, 30mg/kg and 90mg/kg butyphthalide have the acetylcholine of alleviation and histamine brings out the effect of guinea pig trachea spasm.Therefore, butyphthalide has therapeutical effect to asthmatic guinea pigs, and this and butyphthalide suppress Ca
2+the effect of interior stream, expanding tracheal smooth muscles is relevant.
In Integral animal experiment, the effective dose for the treatment of asthma is about 30-90mg/kg body weight, by the conventional Calculation Method of this area, the dosage that is every kilogram of laboratory animal is 5-10 times of every kilogram of dosage of 70kg adult, with this, convert adult's dosage, in butyphthalide, its consumption is 3-18mg/kg body weight; Preferably, its consumption is 5-10mg/kg body weight; More preferably, its consumption is 6mg/kg body weight, and 70kg adult's dosage is 420mg.
In addition, after this compound oral administration or local use, relieving asthma effective, untoward reaction is little, thereby has overcome the defect of current treatment asthmatic medicament.
The specific embodiment
Below by specific embodiment, to the present invention, the application in preparation treatment bronchial asthma medicine elaborates.
The preparation of embodiment 1, butyphthalide soft capsule preparation
Proportioning raw materials: butyphthalide soft capsule is become with medicinal liquid line of oils by capsule material, its herb liquid oil mainly forms by butyphthalide with as the vegetable oil of diluent, the two weight ratio is 1:1 ~ 100, and capsule material is mainly comprised of sizing material, plasticizer, water, and three's part by weight is 1:0.2 ~ 0.4:0.8 ~ 1.30.
Concrete preparation technology is with reference to Chinese patent ZL200310119336.1.
The preparation of embodiment 2, butylphthalide dripping pill
Proportioning raw materials: butylphthalide dripping pill is comprised of active component butyphthalide and substrate, dispersant, coating material.Substrate is selected from Macrogol 4000, polyethylene glycol 6000, PEG 20000, poloxamer.Dispersant is selected from lightweight differential silica gel, polyvinylpolypyrrolidone.Coating material is selected from hypromellose, hydroxypropyl cellulose, ethyl cellulose, Eudragit E30D.
Concrete preparation technology is with reference to Chinese patent ZL200510136358.8.
The preparation of embodiment 3, butyphthalide lyophilized injectable powder
Proportioning raw materials: the lyophilized injectable powder of butyphthalide is mainly made by butyphthalide, emulsifying agent and co-emulsifier, excipient and water for injection, its raw material weight is than helping Ruization Ji ﹕ Fu Xing Ji ﹕ water for injection to equal 5 ~ 8:1 ~ 5:0 ~ 1:4 ~ 10:5 ~ 11 for butylbenzene Tai ﹕ Ruization Ji ﹕.
Preparation technology is with reference to the preparation method of having narrated butyphthalide lyophilized injectable powder in Chinese patent ZL200410012533.8.Preparation method is: by proportioning, weigh each component raw material, first butyphthalide is added together with co-emulsifier part water for injection high-speed stirred even with emulsifying agent; Separately get part water for injection excipient dissolving, add the active carbon that accounts for gross weight 0.1%, 100 ℃ of heating take off charcoal after 15 minutes, after again two kinds of solution being mixed, the active carbon that adds gross weight 0.0l%, filters, takes off charcoal, and benefit adds to the full amount of water for injection, survey pH value, content, after fine straining, in medicinal liquid sub-bottling, lyophilizing obtains butyphthalide lyophilized injectable powder.
The preparation of embodiment 4, butyphthalide tablet
Proportioning raw materials: butyphthalide tablet is mainly comprised of butyphthalide pressed powder and other pharmaceutic adjuvants, wherein butyphthalide pressed powder by weight percentage, by 9 ~ 30% butyphthalides, 0.01 ~ 1.2% emulsifying agent, 70 ~ 90% cyclodextrin or cyclodextrin derivative form.
Concrete preparation technology is with reference to the preparation method of Chinese patent ZL200710062273.9 butyphthalide tablet.
The preparation of embodiment 5, butyphthalide tablet
Proportioning raw materials: butyphthalide tablet is mainly comprised of butyphthalide pressed powder and other pharmaceutic adjuvants, wherein butyphthalide pressed powder by weight percentage, by 5 ~ 20% butyphthalides, 4 ~ 10% aminophyllines, 0.01 ~ 1.2% emulsifying agent, 70 ~ 90% cyclodextrin or cyclodextrin derivative form.
Concrete preparation technology is with reference to the preparation method of butyphthalide tablet in Chinese patent ZL200710062273.9.
The preparation of embodiment 6, butyphthalide tablet
Proportioning raw materials: butyphthalide tablet is mainly comprised of butyphthalide pressed powder and other pharmaceutic adjuvants, wherein butyphthalide pressed powder by weight percentage, by 8 ~ 25% butyphthalides, 1 ~ 5% ephedrine, 0.01 ~ 1.2% emulsifying agent, 70 ~ 90% cyclodextrin or cyclodextrin derivative form.
Concrete preparation technology is with reference to the preparation method of Chinese patent ZL200710062273.9 butyphthalide tablet.
The preparation of embodiment 7, butyphthalide tablet
Proportioning raw materials: butyphthalide tablet is mainly comprised of butyphthalide pressed powder and other pharmaceutic adjuvants, wherein butyphthalide pressed powder by weight percentage, by 8 ~ 27% butyphthalides, 1 ~ 3% sodium cromoglicate, 0.01 ~ 1.2% emulsifying agent, 70 ~ 90% cyclodextrin or cyclodextrin derivative form.
Concrete preparation technology is with reference to the preparation method of butyphthalide tablet in Chinese patent ZL200710062273.9.
The preparation of embodiment 8, butyphthalide tablet
Proportioning raw materials: butyphthalide tablet is mainly comprised of butyphthalide pressed powder and other pharmaceutic adjuvants, wherein butyphthalide pressed powder by weight percentage, by 5 ~ 17% butyphthalides, 3 ~ 10% aminophyllines, 1 ~ 3% sodium cromoglicate, 0.01 ~ 1.2% emulsifying agent, 70 ~ 90% cyclodextrin or cyclodextrin derivative form.
Concrete preparation technology is with reference to the preparation method of butyphthalide tablet in Chinese patent ZL200710062273.9.
The preparation of embodiment 9, butyphthalide tablet
Proportioning raw materials: butyphthalide tablet is mainly comprised of butyphthalide pressed powder and other pharmaceutic adjuvants, wherein butyphthalide pressed powder by weight percentage, by 7 ~ 22% butyphthalides, 1 ~ 5% ephedrine, 1 ~ 3% sodium cromoglicate, 0.01 ~ 1.2% emulsifying agent, 70 ~ 90% cyclodextrin or cyclodextrin derivative form.
Concrete preparation technology is with reference to the preparation method of butyphthalide tablet in Chinese patent ZL200710062273.9.
The preparation of embodiment 10, butyphthalide tablet
Proportioning raw materials: butyphthalide tablet is mainly comprised of butyphthalide pressed powder and other pharmaceutic adjuvants, wherein butyphthalide pressed powder by weight percentage, by 5 ~ 15% butyphthalides, 2 ~ 9% aminophyllines, 1 ~ 4% ephedrine, 1 ~ 2% sodium cromoglicate, 0.01 ~ 1.2% emulsifying agent, 70 ~ 90% cyclodextrin or cyclodextrin derivative form.
Concrete preparation technology is with reference to the preparation method of butyphthalide tablet in Chinese patent ZL200710062273.9.
Claims (4)
1. the application of butyphthalide in preparing bronchiectasis suppressing panting calming medicine.
2. the application of butyphthalide in preparing bronchiectasis suppressing panting calming medicine as claimed in claim 1, is characterized in that: be to take butyphthalide as main active, according to technique available on pharmaceutics and adjuvant, be prepared into any preparation.
3. the application of butyphthalide in preparing bronchiectasis suppressing panting calming medicine as claimed in claim 1, is characterized in that: described butyphthalide combines with the medicine with treatment asthma function, jointly as active substance.
4. the application of butyphthalide in preparing bronchiectasis suppressing panting calming medicine as claimed in claim 3, is characterized in that: described in there is treatment asthma function medicine be at least one in aminophylline, Oxtriphylline, diprophylline, ephedrine, albuterol, Clenbuterol, sodium cromoglicate, ipratropium bromide, beclometasone, budesonide, nifedipine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210316146.8A CN102793696B (en) | 2012-08-31 | 2012-08-31 | Application of butylphthalide in preparation of medicament for treating bronchial asthma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210316146.8A CN102793696B (en) | 2012-08-31 | 2012-08-31 | Application of butylphthalide in preparation of medicament for treating bronchial asthma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102793696A CN102793696A (en) | 2012-11-28 |
| CN102793696B true CN102793696B (en) | 2014-09-10 |
Family
ID=47193167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210316146.8A Expired - Fee Related CN102793696B (en) | 2012-08-31 | 2012-08-31 | Application of butylphthalide in preparation of medicament for treating bronchial asthma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102793696B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017198114A1 (en) * | 2016-05-19 | 2017-11-23 | 长弘生物科技股份有限公司 | Pharmaceutical formulation for delaying incidence and/or treatment of pulmonary fibrosis |
| CN106580959B (en) * | 2017-01-10 | 2019-04-23 | 山东省立医院 | A kind of butylphenyl phthaleine Nitrendipine soft capsule for alleviating acute ischemic cerebral apoplexy |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100298427A1 (en) * | 2005-05-24 | 2010-11-25 | Dsm Ip Assets B.V. | Anti-inflammatory compositions and their use |
-
2012
- 2012-08-31 CN CN201210316146.8A patent/CN102793696B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100298427A1 (en) * | 2005-05-24 | 2010-11-25 | Dsm Ip Assets B.V. | Anti-inflammatory compositions and their use |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102793696A (en) | 2012-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106163499A (en) | Nasal medicine product and using method thereof | |
| CN101357146B (en) | Preparation method of chimonanthus nitens valid target, production method and use of formulation thereof | |
| CN101366844B (en) | New use of loquat flower and its extract | |
| CN103083525A (en) | Traditional Chinese medicine composition for treating asthma, as well as preparation method and use of composition | |
| CN103432184A (en) | Application of great burdock fruit extract in drug production or foods | |
| CN102793696B (en) | Application of butylphthalide in preparation of medicament for treating bronchial asthma | |
| CN104800236B (en) | Asarum total polysaccharide extractive and its extracting method and application with antitussive activity | |
| CN102895326B (en) | Traditional Chinese medicine composition for treating infantile common cold and preparation method for traditional Chinese medicine composition | |
| CN103989695B (en) | A kind of pharmaceutical composition and application thereof treating bronchial asthma | |
| CN101856438B (en) | Medicinal composition for treating infant asthma and preparation method and use thereof | |
| CN109793740A (en) | Application of the pazopanib hydrochloride in preparation treatment pulmonary fibrosis disease drug | |
| CN108938650A (en) | The application of cinobufagin | |
| CN100349568C (en) | Intravenous administered injection of ginkgolide B, its preparation method and application | |
| CN102302504A (en) | Application of high-purity baicalin or baicalein to preparation of inhaled asthma relieving medicament | |
| CN101991811B (en) | Traditional Chinese medicine composition for treating rheumatism arthralgia, cold headache, abdominal cavity pain and chilblain and preparation method thereof | |
| CN100435817C (en) | Medicine for treating rheumatism and rheumatoid diseases and preparing method | |
| CN101791353A (en) | Sustained-release matrix type compound Chuanping sustained-release tablet and preparation method and application thereof | |
| CN101721437B (en) | Preparation method of medicine composition used for treating chronic pharyngitis | |
| CN100493501C (en) | Scopolamine hydrobromide dry powder inhalant for nose and preparing method | |
| CN107773593A (en) | A kind of infantile heat-clearing and antitussive Neulized inhalation pharmaceutical solutions and preparation method thereof | |
| CN103919789A (en) | Ultrasonic atomization steam inhalation treatment method of ephedrine composition | |
| CN1212116C (en) | Sophorcarpidine alkaloid and decongestant compound medicine and its preparation method | |
| CN102188600B (en) | Chinese medicinal preparation for treating tracheitis and preparation method thereof | |
| CN101904859B (en) | Rhoifolin and hyperin composition and application of medicines prepared therefrom | |
| CN102225082A (en) | Medicament for preventing and treating diabetes and complications thereof and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140910 Termination date: 20200831 |